Work

Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.4_suppl.336

Authors: Charalampos S. Floudas, Changqing Xie, Gagandeep Brar, Maria Pia Morelli, Suzanne Fioravanti, Melissa Walker, Donna Mabry-Hrones, Brad J. Wood, Elliot B Levy, Venkatesh P Krishnasamy, Tim F. Greten

Institutions: National Cancer Institute, National Institutes of Health

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2913248633

Cites:

Cited by: 43

Related to: 10